Peer-reviewed veterinary case report
Stem cell treatment effects on thinking and movement in older dogs
By Kim, Tae-Yoon et al.·Published in Frontiers in veterinary science·2025·Bio Research and Development Center, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of cognitive and mobility function in geriatric dogs following treatment with stem cell and stem cell extracellular vesicles derived from embryonic stem cells: a pilot study.
- Species:
- dog
Plain-English summary
A group of older small dogs showing signs of cognitive decline and mobility issues received treatment with stem cells derived from human embryonic sources. After two weeks, their cognitive and mobility functions were assessed, and both groups showed improvements in their symptoms without any significant side effects. This suggests that these stem cell treatments could help older dogs with cognitive dysfunction and mobility problems.
People also search for: dog cognitive dysfunction treatment · elderly dog mobility issues · stem cell therapy for dogs
Abstract
INTRODUCTION: Declining physical or mental health in older dogs can lead to changes in the dog's cognitive and musculoskeletal function. Regrettably, these degenerative changes cannot be remedied. In the present study, geriatric small dogs exhibiting cognitive and behavioral changes were treated with human embryonic stem cell-derived mesenchymal stemcells (ES-MSCs,= 21) and mesenchymal stem cell-derived extracellular vesicles (ES-MSC-EVs,= 21). METHODS: Before and 2 weeks after treatment, the cognitive and mobility status of the dogs were assessed using theCanine Cognitive Dysfunction Rating (CCDR) and the Liverpool Osteoarthritis in Dogs (LOAD) scale. Additionally, safety assessments were conducted through blood tests such as complete blood count and serum chemistry. RESULTS: Following an assessment of clinical symptoms and blood tests in both the groups receiving ES-MSC and ES-MSC-EVs treatments, no notable side effects were detected. Moreover, the questionnaire survey revealed that both groups showed alleviation in CCDR and LOAD scores following administration. DISCUSSION: These findings suggest that ES-MSC and ES-MSC-EV treatments have the potential to be used as a therapeutic option for improving clinical symptoms of degenerative diseases such as canine cognitive dysfunction and degenerativemusculoskeletal diseases in elderly dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40206251/